Biologicals

Medications derived from biotechnological processes have revolutionized therapeutic strategies for various diseases. Recombinant proteins like the monoclonal antibodies used to treat cancer, for example, are produced in cell lines. These, in turn, must be established in laboratory structures that are equipped to construct vectors for expression, cell transfection, selection of producer clone candidates, as well as assays to characterize the lineages and the proteins they produce.

At LNBio, the process of establishing cell lines is conducted in order to create a cell bank for research, which is essential for producing therapeutic proteins in pre-clinical trials that are conducted in in vitro and in vivo models to evaluate safety, dose, and efficacy.

The objective is to establish new scientific and technological competencies that make it possible to generate active pharmaceutical ingredients that are of strategic importance in the production chain for biologicals. This includes lineages that produce recombinant proteins, contributing to Brazilian development of innovative medications and biosimilars that can benefit the public health system.